Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005943 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy in Treating Patients With Metastatic Melanoma
A Phase 1 study of Melanoma (Skin), sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Study location
NCT00005943 is a Phase 1 study of Melanoma (Skin) that has completed, run by University of Colorado, Denver. The trial reports 1 study location across 1 state.
The verdict
NCT00005943, a Phase 1 study of Melanoma (Skin), has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Inserting the gene for interleukin-2 into a person's melanoma cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have metastatic melanoma.
Conditions Studied
Interventions
- BIOLOGICAL aldesleukin
- BIOLOGICAL staphylococcal enterotoxin B
Study Locations (1)
Colorado
- University of Colorado - Denver
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-02 |
| Est. Completion | 2001-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005943
The ClinicalTrials.gov registry entry for NCT00005943 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma (Skin) appearing as the primary indexed condition, and to 2 interventions - of which aldesleukin is the first listed.
NCT00005943 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT00005943 about?
NCT00005943 is a clinical study titled "Gene Therapy in Treating Patients With Metastatic Melanoma". RATIONALE: Inserting the gene for interleukin-2 into a person's melanoma cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have metastatic melanoma.
What is the current status of trial NCT00005943?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-02. Estimated completion is 2001-09.
What conditions does trial NCT00005943 study?
This clinical trial studies the following conditions: Melanoma (Skin).
What interventions are being tested in trial NCT00005943?
The interventions under investigation include: aldesleukin (BIOLOGICAL), staphylococcal enterotoxin B (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005943?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005943 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma (Skin)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
RECRUITING · Phase 1
-
Vaccine Therapy in Treating Patients With Metastatic Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy in Treating Patients With Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
COMPLETED · Phase 1
-
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
COMPLETED · Phase 1
-
Biological Therapy in Treating Patients With Metastatic Melanoma
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.